Cognitive ⏱ Half-life: Not well characterized. Preclinical

PE-22-28

PE-22-28 (Spadin Analog)

Updated March 15, 2026
Buy Now

Evidence at a Glance

Regulatory statusPreclinical
Spadin-derived TREK-1 channel inhibitor; rodent antidepressant candidate, no human trials
Human evidenceNone
Animal evidenceModerate

A shortened spadin analog and TREK-1 potassium-channel inhibitor with antidepressant-like effects and enhanced hippocampal neurogenesis in rodent models, but with no completed or published human efficacy trials.

What the research does not support

  • No human clinical trials have tested it for depression or any other condition.
  • It is not an approved antidepressant.
  • Fast-onset antidepressant claims derive from mouse behavioral assays, not human evidence.
Half-Life
Not well characterized.
Mol. Weight
~800 g/mol

What is PE-22-28?

PE-22-28 represents a novel approach to mood research — targeting TREK-1 potassium channels rather than traditional monoamine pathways. Early animal data suggests rapid-onset effects, distinguishing it from conventional approaches that require weeks.

Research Applications

TREK-1 channel research, rapid-onset mood modulation, serotonergic signaling, hippocampal neurogenesis, and stress resilience models.

Dosage Information (Research Use)

Animal research: 100-500 mcg/kg intranasal or IV. Human dosing not established. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution.

Half-Life & Pharmacokinetics

Not well characterized.

Reported Observations in Literature

Limited data — primarily animal studies. Potassium channel modulation requires careful research protocol design.

Key Research References

  • Moha ou Maati H, et al. “The peptidic antidepressant spadin interacts with prefrontal 5-HT4 and mGluR2 receptors.” Brain Struct Funct. 2016

How PE-22-28 Works

PE-22-28 is a synthetic analog of spadin that blocks TREK-1 potassium channels. TREK-1 channel inhibition increases serotonergic neurotransmission and has shown rapid antidepressant-like effects in rodent models — taking effect within days rather than the weeks required by conventional antidepressants.

Research Findings

Animal data shows rapid onset of mood-modulating effects (4 days vs. 21+ days for SSRIs). Also promotes hippocampal neurogenesis. Very early-stage research — no human clinical trials published.

Dosage & Administration

Animal research: 100-500 mcg/kg intranasal or IV. Human dosing not established. Research use only.

Safety & Side Effects

Limited data — primarily animal studies. Potassium channel modulation requires careful research protocol design.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Heptapeptide derived from sortilin propeptide
Molecular Weight ~800 g/mol
Half-Life Not well characterized.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Moha ou Maati H, et al. "The peptidic antidepressant spadin interacts with prefrontal 5-HT4 and mGluR2 receptors." Brain Struct Funct. 2016

Get PE-22-28 from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Buy Now

Related Peptides

View all →
FGL
Cognitive
NCAM-derived peptide that activates FGFR signaling for memory enhancement and neuroprotection in animal models.
View Profile →
Dihexa
Cognitive
Angiotensin IV analog reported to be 10 million times more potent than BDNF for synaptogenesis in animal models.
View Profile → Buy Now
N-Acetyl Selank
Cognitive
Enhanced-stability version of Selank with improved bioavailability and prolonged anxiolytic/nootropic effects.
View Profile →